SciRhom’s Post

🔬 Mercia Ventures has continued its support into Invizius by leading a £950,000 funding round. The Edinburgh-based biotech company is developing breakthrough treatments for patients on dialysis and the latest investment will enable the company to prepare for the next stage of clinical trials of its H-Guard product and comes in the run-up to a Series B investment round early next year. 📈 H-Guard addresses the inflammatory responses that patients suffer during dialysis which can cause life-threatening complications including damage to organs and the cardiovascular system. Mercia Ventures, who has supported Invizius since 2018, was supported by Calculus Capital, Syensqo, The University of Edinburgh's Old College Capital and Scottish Enterprise. Read more (link in comments) ⏬ #EIS #Investment #VC #VentureCapital #Scotland

👉🏻 ”In Europe, companies tend to spend a lot of time in R&D. The research is well embedded in key scientific fundamentals, there’s a lot of data derived and when you come to due diligence you’ll find that opportunities are very robust — there’s a lot of novelty, and valuations tend to be quite favorable too.” 👈🏻 👀 If this is the general view among US investors, the future should be bright for European and Nordic life science companies. 🤩 The quote above is from the brilliant Natasha Bank’s recent interview with Matthew Konneh, PhD MBA of California based Atheneos Ventures. 💪🏻 Follow BioStock - Connecting Innovation and Capital here on LinkedIn to keep up to date with #Nordic #LifeScience! #VC #VentureCapital #Investments #Innovation

📰 Exciting News! I am thrilled to welcome Michel Spagnol and Eric Garnier to Aenitis Technologies Strategic Advisory Board! Their expertise will be key as we embark on a new chapter in our journey. 🔹 Eric Garnier, former Vice President and General Manager of Pall Medical, joins us as Independent Chairman. His leadership will be crucial in driving revenue and profit growth while establishing new partnerships. 🔹 Michel Spagnol, representing Mifani Invest, brings a wealth of experience from his tenure as former Chairman and CEO of Novasep. His extensive network and insights will help us structure the company for future success. 🧬 The biomanufacturing market has been experiencing significant growth and is expected to continue expanding. As of recent estimates, the global biomanufacturing market was valued at around few hundreds billion euros in 2021 and is projected to double or more by 2028! Together, Aenitis Technologies is set to redefine biomanufacturing and enhance cell therapy with its innovative cell processing solutions. #Acoustophoresis #AcousticLevitation #Deeptech #Innovation #Bioproduction #Biotherapy #CellTherapy #GeneTherapy #Leadership #Innovation #Biomanufacturing #DeepTech #StrategicGrowth #investEU Emmanuel VINCENT Ministère de l'Enseignement supérieur et de la Recherche Ville de Paris ESPCI Paris - PSL Bpifrance Région Ile de France EIT Health CNRS Innovation Weaving Invest Svetoslava Georgieva European Innovation Council and SMEs Executive Agency (EISMEA) European Investment Fund (EIF) European Investment Bank (EIB) Idir Idjerouidene Jean-Luc AIDER Fermin Sanchez-Guijo Mickaël Tanter Miquel Lozano chaouqi misbah Mauricio Hoyos Jean-Francois Leprince Skander Rollet Jacky Harrouet

One of the biotech industry's star investors, the 38-year-old VC firm ARCH Venture Partners, uncorked its 13th fund on Thursday. The Chicago-based firm has another $3 billion to deploy into its large bets on neuroscience, AI, obesity, autoimmune diseases and other areas ripe for more precise treatments. “We’re trying to slow down, but not slowing down because there’s so much cool stuff right now,” managing director Bob Nelsen said Wednesday in an interview with Endpoints News. “Every time we think we’re going to slow down, AI happens or some other thing happens, so it’s an amazing environment to start companies, small ones or big ones, and we do both.” The firm has dished out larger checks and created more startups than most other biotech VC investors over the years. Its current roster includes Xaira Therapeutics, Mirador Therapeutics, Seaport Therapeutics and Metsera among dozens of others. “I’m very hopeful over the next 10 years, and certainly the life of Fund XIII, that we’ll continue to evolve the precision medicine models so that we can better serve patients with lupus, with rheumatoid arthritis, with metabolic disease, cardiovascular disease,” managing director Kristina Burow said in an interview. “Those aren’t just giant, lump diseases. We’re going to start to be able to parse different patients into different medicines.” #biotech #venturecapital #arch #biotechvc #vcfirm #lifesciences

WE.DO.HEALTHCARE🚀🚀 I am pleased to share this to show once again that we advise innovative #Biomedical, #MedTech and #PharmaTech start-ups in a highly regulated area, in order to make a small contribution to even better medicine. ➡️ Periprosthetic infections lead to numerous avoidable medical malpractice cases. A periprosthetic joint infection is an infection of the peri-implant tissue of an artificial joint implanted in the body. The number of joint replacement surgeries has been increasing for years due to the ageing population and the increasing demands of patients who want to remain active into old age. InfectoTest GmbH is thus another example of an innovation that can make a significant contribution. Dr. Marc-André Rousseau

Exciting Investment to Support Nuclera's Vision of Expanding Protein Access to Researchers Worldwide! 🌍 If you want to learn more about the eProtein Discovery System, join me for Nuclera's upcoming webinar, "Defying Difficult-to-Express Proteins." Sign up using this link: https://eprote.in/OCT22 📅 Date: Tuesday, October 22 🕚 Time: 11 AM US / 4 PM UK Covering: 📊 Expressing proteins with disordered regions, toxic binding domains, and disulfide bonds in just 48 hours. 🔬 Screening 192 expression conditions in 24 hours using digital microfluidics and cell-free protein synthesis. 🧪 Using cell-free systems to guide cell-based production. I’m looking forward to seeing you there! #ProteinScience #CellFreeProteinSynthesis #MolecularBiology #DrugDiscovery #ResearchAndDevelopment

📯 Axoltis Pharma's team is very proud to be among the #PrixGalien USA Award nominees for "Best Startup" !   This year marks the tenth anniversary of The Galien Foundation and Business France recognizing global innovators in the "Best Startup" category. This partnership supports global healthcare startups by offering visibility on the American stage and connecting them with major players in the industry in the U.S. and Canada. Axoltis aims to expand its current panel of collaborations with academic labs and with potential pharma partners in the world, especially in North America to explore the broad range of indications of its patented lead product #NX210c.   NX210c could change the game in the treatment of neurodegenerative diseases. Aside to a neuroprotective effect, its main property is the recovery of the blood brain barrier integrity which is impaired in a broad range of diseases. Axoltis has just launched a phase II clinical trial in Amyotrophic Lateral Sclerosis (#ALS), where the #BBB is impaired since the early stages of the disease. ALS is a fatal disease with a huge unmet medical need.. #PrixGalienUSA #BusinessFranceNorthAmerica #FrenchHealthcare #ChooseFrance

Today's the day to take the first steps towards entrepreneurship. Get informed! See you at 4 pm online!

Exciting News: Avelo Receives a 1.5M Innosuisse Grant!   Following the Eurostars grant in October, our portfolio company Avelo, a Swiss breath diagnostics start-up, has been awarded a CHF 1.5M Innosuisse Startup Innovation Project to further develop a new breath sampling device called AveloCollect.   This 34-month project leverages Avelo’s ongoing Eurostars project and will focus on clinical development and market readiness for AveloCollect. This device’s compatibility with various respiratory pathogens positions this product as a potential game changer for roll-out in European markets and offers opportunities for global commercial partnerships.   This is a significant step towards saving lives and reducing healthcare costs. 🎉🎉🎉   Read more here: https://lnkd.in/dn_Get63   Melanie Aregger, Tobias Broger; Innosuisse   #diagnostics #betterdiagnostics #makingadifference #aerosols #noninvasivesampling #breathtest #moleculardiagnostics #respiratoryinfections  

RiverVest managing director Niall O'Donnell shares the stage at the American Thoracic Society's #ATS2024 Respiratory Innovation Summit (#RIS2024) with Geeta Vemuri of Agent Capital, Bernard Davitian of Omega Funds, Drew Field of Bain Capital Life Sciences Fund LP, Katarina Pance, PhD of SR One Capital Management, and moderator Brian Matesic, MD of Norwest Venture Partners. The panel discussed investing in respiratory companies including strategies, challenges, due diligence, and advice for entrepreneurs. Niall’s key messages were: 1. Put patients first 2. Assemble a strong biotech team 3. Advocate for refined orphan disease language in the Inflation Reduction Act (#IRA) of 2022 The language used in the IRA is of enormous concern to RiverVest Venture Partners and others in the life sciences arena. It unintentionally curtails efforts to pursue future follow-on indications for approved orphan disease treatments. Innovators need to see economic justification in developing a drug for a small market, and being able to apply the same drug to multiple needs has often been the way that companies could justify such investments. Thank you Lyn Baranowski for inviting Niall to join you at ATS/ RIS. RiverVest portfolio company Avalyn Pharma Inc. is developing inhaled formulations of approved medications to treat rare respiratory diseases with an initial focus on interstitial lung diseases, including pulmonary fibrosis. Isaac Zike Ph.D. Pascal Krotee, Ph.D. Dustin Bell, PMP #lungdisease #respiratorycompanies #americanthoracicsociety #raredisease #orphandrugs